Ewa Mędraś

Long-term outcomes with frontline nilotinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase: ENESTnd 10-year analysis

Hagop M. Kantarjian, Timothy P. Hughes, Richard A. Larson et al. · Leukemia · 2021 · 332 citations · Full text

Real-life comparison of severe vascular events and other non-hematological complications in patients with chronic myeloid leukemia undergoing second-line nilotinib or dasatinib treatment

Joanna Góra‐Tybor, Ewa Mędraś, Małgorzata Całbecka et al. · Leukemia & lymphoma/Leukemia and lymphoma · 2015 · 40 citations

Mixed-phenotype Acute Leukemia, Pathology, Pharmacotherapy +17

Long-Term Outcomes in Patients with Chronic Myeloid Leukemia in Chronic Phase Receiving Frontline Nilotinib Versus Imatinib: Enestnd 10-Year Analysis

Timothy P. Hughes, Giuseppe Saglio, Richard A. Larson et al. · Blood · 2019 · 27 citations

Quality of Life and Adherence to Therapy in Patients With Chronic Myeloid Leukemia Treated With Nilotinib as a Second-Line Therapy: A Multicenter Prospective Observational Study

Tomasz Sacha, Joanna Góra‐Tybor, Ewa Wąsak-Szulkowska et al. · Clinical Lymphoma Myeloma & Leukemia · 2017 · 15 citations · Full text

Hematological Malignancy, Quality Of Life, Medicine +9

Correction to: Long-term outcomes with frontline nilotinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase: ENESTnd 10-year analysis

Hagop M. Kantarjian, Timothy P. Hughes, Richard A. Larson et al. · Leukemia · 2021 · 11 citations · Full text

Chronic Phase, Hematological Malignancy, Chronic Myeloid Leukemia +7